Evaluating the Clinical Benefits of EOScu
EOS Surfaces and Cupron joined with Sentara Healthcare to evaluate the clinical and economic effectiveness of installing EOScu Preventive|Biocidal surfaces and antimicrobial textiles in a range of healthcare environments.
Committed to combating the spread of pathogens that contribute to healthcare infections, EOScu Preventive|Biocidal Surface™ and Cupron-enhanced textiles are being evaluated at multiple sites. The study will assess the improvement of patient outcomes and reduction of healthcare costs.
This comprehensive trial is the world’s largest known hospital evaluation of biocidal materials to date.
The trial started in April 2014 at Sentara Norfolk, and will be followed by a large-scale study taking place at Sentara Leigh Hospital in Norfolk, VA.
The large-scale Trial includes:
- The installation of more than 15,000 horizontal square feet of patent-pending EOScu Preventive|Biocidal surfaces
- Preventive|Biocidal hard surfaces installed on virtually all clinical and patient-room surfaces, including over bed tables and bed rails
- Anti-odor textiles manufactured by the Encompass Group are used for patient bed linens, patient gowns, and other textiles
“Sentara is pleased to become the first large-scale deployment of these advanced antimicrobial materials. Over the years, Sentara has implemented many advanced practices in an effort to minimize hospital-acquired infections (HAIs) at our facilities and we believe that new technologies, such as the Cupron-enhanced materials, have the potential to create another layer of protection in this very important effort.”
– Gene Burke, MD,
Vice President of Clinical
Effectiveness for Sentara
See the EOScu difference
Request a sample today